Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study

导出原文传递

翻译打印收藏纠错

作者： Gattorno, Marco ^[1] ; Obici, Laura ^[2] ; Cattalini, Marco ^[3] ; Tormey, Vincent ^[4] ; Abrams, Ken ^[5] ; Davis, Nicole ^[6] ; Speziale, Antonio ^[7] ; Bhansali, Suraj G. ; Martini, Alberto ; Lachmann, Helen J.

作者单位： Fdn IRCCS Policlin San Matteo, Amyloidosis Res & Treatment Ctr, Biotechnol Res Labs, Pavia, Italy ^[1] UCL, Sch Med, Div Med, Natl Amyloidosis Ctr, London, England ^[2] G Gaslini Inst Children, UO Pediat 2, Reumatol, Eurofever Project, Genoa, Italy ^[3] Galway Univ Hosp, Galway, Ireland ^[4] Novartis Pharmaceut, E Hanover, NJ USA ^[5] Univ Brescia, Pediat Clin, Brescia, Italy ^[6] Novartis Pharma AG, Basel, Switzerland ^[7]

发布时间 2017-06-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览1

Annals of the Rheumatic Diseases

2017年76卷1期

173-178页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study

Annals of the Rheumatic Diseases

相似文献

Annals of the Rheumatic Diseases

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study

Annals of the Rheumatic Diseases

相似文献

Annals of the Rheumatic Diseases

相关期刊

检索历史清除